{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:14:29Z","timestamp":1784956469759,"version":"3.55.0"},"reference-count":134,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205933","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T18:52:18Z","timestamp":1540407138000},"page":"e0205933","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins"],"prefix":"10.1371","volume":"13","author":[{"given":"Heidar Ali","family":"Panahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Bolhassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Noormohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"E-M de Villiers","year":"2013","journal-title":"Virology"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.mjafi.2015.02.006","article-title":"HPV vaccine: Current status and future directions","volume":"71","author":"S Kumar","year":"2015","journal-title":"Medical journal, Armed Forces India"},{"key":"ref3","article-title":"The natural history of human papillomavirus infection","author":"S de Sanjos\u00e9","year":"2017","journal-title":"Best Practice & Research Clinical Obstetrics & Gynaecology"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"HU Bernard","year":"2010","journal-title":"Virology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"D Forman","year":"2012","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"M Schiffman","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"S1","key":"ref7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25","author":"J Doorbar","year":"2015","journal-title":"Rev Med Virol"},{"issue":"1732","key":"ref8","doi-asserted-by":"crossref","first-page":"20160268","DOI":"10.1098\/rstb.2016.0268","article-title":"Tumour virus vaccines: hepatitis B virus and human papillomavirus","volume":"372","author":"M Stanley","year":"2017","journal-title":"Phil Trans R Soc B"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"C Martel","year":"2012","journal-title":"The Lancet Oncology"},{"key":"ref10","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","author":"C de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"FX Bosch","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.virol.2013.07.018","article-title":"Human papillomavirus genome variants","volume":"445","author":"RD Burk","year":"2013","journal-title":"Virology"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"P Guan","year":"2012","journal-title":"International journal of cancer"},{"key":"ref14","first-page":"1","article-title":"Human papillomaviruses","volume":"90","year":"2007","journal-title":"IARC Monographs on the evaluation of carcinogenic risks to humans"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/ijc.22089","article-title":"E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain","volume":"119","author":"GH Ashrafi","year":"2006","journal-title":"Int J Cancer"},{"issue":"51","key":"ref16","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1038\/sj.onc.1205885","article-title":"The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface","volume":"21","author":"B Marchetti","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"M Scheffner","year":"1990","journal-title":"Cell"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1128\/JVI.75.16.7583-7591.2001","article-title":"Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7","volume":"75","author":"SL Gonzalez","year":"2001","journal-title":"Journal of virology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"J Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"e1006211","DOI":"10.1371\/journal.ppat.1006211","article-title":"The role of integration in oncogenic progression of HPV-associated cancers","volume":"13","author":"AA McBride","year":"2017","journal-title":"PLoS Path"},{"issue":"Supplement 1","key":"ref21","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"M Stanley","year":"2006","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/1874357901206010264","article-title":"Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach","volume":"6","author":"K Kawana","year":"2012","journal-title":"Open Virol J"},{"issue":"1\u20132","key":"ref23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-1702(02)00123-5","article-title":"Evasion of host immunity directed by papillomavirus-encoded proteins","volume":"88","author":"PM O'Brien","year":"2002","journal-title":"Virus Res"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2008.11.017","article-title":"Papillomavirus E6 proteins","volume":"384","author":"HL Howie","year":"2009","journal-title":"Virology"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2013.05.006","article-title":"The E5 proteins","volume":"445","author":"D DiMaio","year":"2013","journal-title":"Virology"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.virol.2013.04.013","article-title":"The papillomavirus E7 proteins","volume":"445","author":"A Roman","year":"2013","journal-title":"Virology"},{"key":"ref27","article-title":"A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6\/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect","author":"J Li","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"MH Einstein","year":"2007","journal-title":"Gynecologic oncology"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope\u2010containing peptide protects against a tumor induced by human papillomavirus type 16\u2010transformed cells","volume":"23","author":"MC eltkamp","year":"1993","journal-title":"Eur J Immunol"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/j.vaccine.2007.01.010","article-title":"Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection","volume":"25","author":"PR Manuri","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-06-2916","article-title":"HLA-DQB1* 02\u2013restricted HPV-16 E7 peptide\u2013specific CD4+ T-cell immune responses correlate with regression of HPV-16\u2013associated high-grade squamous intraepithelial lesions","volume":"13","author":"S Peng","year":"2007","journal-title":"Clinical cancer research"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"JW Wang","year":"2013","journal-title":"Virology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"JT Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"EA Joura","year":"2015","journal-title":"New Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"JT Schiller","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00262-006-0247-2","article-title":"Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice","volume":"56","author":"JG Gomez-Gutierrez","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"MC Cassetti","year":"2004","journal-title":"Vaccine"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/BF02254996","article-title":"Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects","volume":"9","author":"W-F Cheng","year":"2002","journal-title":"J Biomed Sci"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11373-006-9086-6","article-title":"A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity","volume":"13","author":"C-T Lin","year":"2006","journal-title":"J Biomed Sci"},{"issue":"16","key":"ref40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/gt.2008.53","article-title":"Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects","volume":"15","author":"S Peng","year":"2008","journal-title":"Gene Ther"},{"issue":"32","key":"ref41","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1016\/j.vaccine.2007.05.041","article-title":"Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours","volume":"25","author":"AG Chandy","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3892\/ijo_00000528","article-title":"Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines","volume":"36","author":"M Reinis","year":"2010","journal-title":"Int J Oncol"},{"issue":"23","key":"ref43","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/S0264-410X(03)00237-8","article-title":"Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines","volume":"21","author":"DM Da Silva","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"ref44","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus\u2010like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"AM Kaufmann","year":"2007","journal-title":"Int J Cancer"},{"issue":"7","key":"ref45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.humimm.2005.04.006","article-title":"Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro","volume":"66","author":"DE Warrino","year":"2005","journal-title":"Human immunology"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","volume":"15","author":"P Vici","year":"2016","journal-title":"Expert review of vaccines"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.vaccine.2011.11.002","article-title":"HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX B\/E","volume":"30","author":"R Paris","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.humimm.2015.11.012","article-title":"Major histocompatibility complex linked databases and prediction tools for designing vaccines","volume":"77","author":"SP Singh","year":"2016","journal-title":"Human Immunology"},{"key":"ref49","article-title":"Cellular and Molecular Immunology","author":"AK Abbas","year":"2014"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"H-H Bui","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"J Sidney","year":"2008","journal-title":"BMC Immunol"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00005-010-0067-0","article-title":"CD4+ T cell epitope discovery and rational vaccine design","volume":"58","author":"DS Rosa","year":"2010","journal-title":"Archivum immunologiae et therapiae experimentalis"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"e11072","DOI":"10.1371\/journal.pone.0011072","article-title":"A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules","volume":"5","author":"SP Ribeiro","year":"2010","journal-title":"PLoS One"},{"issue":"3\u20134","key":"ref54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"H-G Rammensee","year":"1999","journal-title":"Immunogenetics"},{"key":"ref55","first-page":"149518","article-title":"NetMHCpan 4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","author":"VI Jurtz","year":"2017","journal-title":"bioRxiv"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/icb.2010.65","article-title":"Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses","volume":"89","author":"D Sirskyj","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.CR0070056","article-title":"Prediction of T-cell epitope","volume":"105","author":"H Tsurui","year":"2007","journal-title":"Journal of pharmacological sciences"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0092-8674(93)90472-3","article-title":"Prominent role of secondary anchor residues in peptide binding to HLA-A2. 1 molecules","volume":"74","author":"J Ruppert","year":"1993","journal-title":"Cell"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"M Nielsen","year":"2016","journal-title":"Genome Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"D405","DOI":"10.1093\/nar\/gku938","article-title":"The immune epitope database (IEDB) 3.0","volume":"43","author":"R Vita","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"ref61","unstructured":"Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Mena M, et al. Human Papillomavirus and Related Diseases in the World. Summary Report 27 July 2017. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). 2017:1\u2013325."},{"issue":"9","key":"ref62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00018-005-4528-2","article-title":"Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding","volume":"62","author":"S Tenzer","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/1471-2105-11-568","article-title":"Peptide binding predictions for HLA DR, DP and DQ molecules","volume":"11","author":"P Wang","year":"2010","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"ref64","doi-asserted-by":"crossref","first-page":"e1000048","DOI":"10.1371\/journal.pcbi.1000048","article-title":"A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach","volume":"4","author":"P Wang","year":"2008","journal-title":"PLoS Comp Biol"},{"key":"ref65","unstructured":"Immune Epitope Database and analysis resource (IEDB) 3.0. MHC-I processing predictions\u2014Tutorial; National Institute of Allergy and Infectious Diseases; 2018; [updated: January 07, 2018]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/tools.iedb.org\/processing\/help\/\" xlink:type=\"simple\">http:\/\/tools.iedb.org\/processing\/help\/<\/ext-link>."},{"issue":"9","key":"ref66","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"V Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-60327-118-9_13","article-title":"Prediction of peptide-MHC binding using profiles","author":"PA Reche","year":"2007","journal-title":"Immunoinformatics: Predicting Immunogenicity In Silico"},{"issue":"9","key":"ref68","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0198-8859(02)00432-9","article-title":"Prediction of MHC class I binding peptides using profile motifs","volume":"63","author":"PA Reche","year":"2002","journal-title":"Human immunology"},{"issue":"7","key":"ref69","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nbt1215","article-title":"A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus","volume":"24","author":"M Moutaftsi","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ref70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"I Hoof","year":"2009","journal-title":"Immunogenetics"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","article-title":"Gapped sequence alignment using artificial neural networks: application to the MHC class I system","volume":"32","author":"M Andreatta","year":"2016","journal-title":"Bioinformatics"},{"issue":"suppl_2","key":"ref72","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8\u201311","volume":"36","author":"C Lundegaard","year":"2008","journal-title":"Nucleic acids research"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2105-10-394","article-title":"Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior","volume":"10","author":"Y Kim","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2105-6-132","article-title":"Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method","volume":"6","author":"B Peters","year":"2005","journal-title":"BMC Bioinformatics"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1745-7580-4-2","article-title":"Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries","volume":"4","author":"J Sidney","year":"2008","journal-title":"Immunome Res"},{"issue":"10","key":"ref76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/bioinformatics\/btp137","article-title":"The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding","volume":"25","author":"H Zhang","year":"2009","journal-title":"Bioinformatics"},{"issue":"3","key":"ref77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00251-011-0579-8","article-title":"NetMHCcons: a consensus method for the major histocompatibility complex class I predictions","volume":"64","author":"E Karosiene","year":"2012","journal-title":"Immunogenetics"},{"issue":"4","key":"ref78","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-Specific Prediction of Peptide\u2013MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity","volume":"197","author":"M Rasmussen","year":"2016","journal-title":"The Journal of Immunology"},{"key":"ref79","unstructured":"BMI (Biomedical Informatics)-Heidelberg. Information on SYFPEITHI. institute for cell biology-department of immunology-Heidelberg; 2012; [updated: 27 Aug 2017]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.syfpeithi.de\/bin\/MHCServer.dll\/Info.htm\" xlink:type=\"simple\">http:\/\/www.syfpeithi.de\/bin\/MHCServer.dll\/Info.htm<\/ext-link>."},{"issue":"11\u201312","key":"ref80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00251-015-0873-y","article-title":"Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification","volume":"67","author":"M Andreatta","year":"2015","journal-title":"Immunogenetics"},{"issue":"1","key":"ref81","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2105-10-296","article-title":"NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction","volume":"10","author":"M Nielsen","year":"2009","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"ref82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1471-2105-8-238","article-title":"Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method","volume":"8","author":"M Nielsen","year":"2007","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"ref83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/9858","article-title":"Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices","volume":"17","author":"T Sturniolo","year":"1999","journal-title":"Nat Biotechnol"},{"issue":"4","key":"ref84","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4049\/jimmunol.171.4.1741","article-title":"Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors","volume":"171","author":"B Peters","year":"2003","journal-title":"The Journal of Immunology"},{"issue":"10","key":"ref85","doi-asserted-by":"crossref","first-page":"e1003266","DOI":"10.1371\/journal.pcbi.1003266","article-title":"Properties of MHC class I presented peptides that enhance immunogenicity","volume":"9","author":"JJ Calis","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"HH Bui","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"D1","key":"ref87","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"FF Gonz\u00e1lez-Galarza","year":"2014","journal-title":"Nucleic acids research"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ymeth.2015.07.004","article-title":"Modeling of protein\u2013peptide interactions using the CABS-dock web server for binding site search and flexible docking","volume":"93","author":"M Blaszczyk","year":"2016","journal-title":"Methods"},{"issue":"W1","key":"ref89","doi-asserted-by":"crossref","first-page":"W419","DOI":"10.1093\/nar\/gkv456","article-title":"CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site","volume":"43","author":"M Kurcinski","year":"2015","journal-title":"Nucleic Acids Research"},{"issue":"1","key":"ref90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3349\/ymj.2006.47.1.1","article-title":"Human papillomavirus type 16 E5 protein as a therapeutic target","volume":"47","author":"S-W Kim","year":"2006","journal-title":"Yonsei Med J"},{"issue":"6","key":"ref91","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/JVI.74.6.2888-2894.2000","article-title":"Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer","volume":"74","author":"D-W Liu","year":"2000","journal-title":"Journal of virology"},{"issue":"5","key":"ref92","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines","volume":"8","author":"CJ Melief","year":"2008","journal-title":"Nature Reviews Cancer"},{"issue":"5","key":"ref93","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"AW Purcell","year":"2007","journal-title":"Nature reviews Drug discovery"},{"issue":"19","key":"ref94","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2017.03.025","article-title":"Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6\/E7","volume":"35","author":"KY Tsang","year":"2017","journal-title":"Vaccine"},{"issue":"28","key":"ref95","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.2174\/138161209789105162","article-title":"Prediction of MHC-peptide binding: a systematic and comprehensive overview","volume":"15","author":"EM Lafuente","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"1","key":"ref96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10989-015-9492-6","article-title":"Prediction of epitope-based peptides for vaccine development from coat proteins GP2 and VP24 of Ebola virus using immunoinformatics","volume":"22","author":"PN Srivastava","year":"2016","journal-title":"International Journal of Peptide Research and Therapeutics"},{"issue":"8","key":"ref97","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL priming by exact peptide epitopes in incomplete Freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity","volume":"179","author":"MS Bijker","year":"2007","journal-title":"The Journal of Immunology"},{"issue":"5","key":"ref98","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biologicals.2015.07.002","article-title":"Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: An in silico approach","volume":"43","author":"A Kumar","year":"2015","journal-title":"Biologicals"},{"issue":"1","key":"ref99","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vacun.2016.03.001","article-title":"Computational prediction of linear B-cell epitopes in the E5 oncoprotein of the human papillomavirus type 16 using several bioinformatics tools","volume":"17","author":"JB Lissabet","year":"2016","journal-title":"Vacunas"},{"issue":"203","key":"ref100","first-page":"2379","article-title":"Multi Epitope Peptide Vaccine Prediction against Sudan Ebola Virus Using Immuno-Informatics Approaches","volume":"5","author":"AH Abu-haraz","year":"2017","journal-title":"Adv Tech Biol Med"},{"issue":"2","key":"ref101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cellimm.2007.02.005","article-title":"A systematic bioinformatics approach for selection of epitope-based vaccine targets","volume":"244","author":"AM Khan","year":"2006","journal-title":"Cell Immunol"},{"issue":"Supplement C","key":"ref102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtbi.2014.01.018","article-title":"A novel multi-epitope peptide vaccine against cancer: An in silico approach","volume":"349","author":"N Nezafat","year":"2014","journal-title":"J Theor Biol"},{"issue":"12","key":"ref103","doi-asserted-by":"crossref","first-page":"e0144475","DOI":"10.1371\/journal.pone.0144475","article-title":"Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases","volume":"10","author":"J Shi","year":"2015","journal-title":"PloS one"},{"issue":"14","key":"ref104","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2174\/156802612802652402","article-title":"Advances in peptide-based human papillomavirus therapeutic vaccines","volume":"12","author":"TY Liu","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"45","key":"ref105","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1016\/j.vaccine.2005.04.049","article-title":"Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model","volume":"23","author":"A Vambutas","year":"2005","journal-title":"Vaccine"},{"issue":"9","key":"ref106","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope\u2010containing peptide protects against a tumor induced by human papillomavirus type 16\u2010transformed cells","volume":"23","author":"MC Feltkamp","year":"1993","journal-title":"Eur J Immunol"},{"issue":"9","key":"ref107","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/eji.1830250935","article-title":"Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16\u2010induced tumors","volume":"25","author":"MC Feltkamp","year":"1995","journal-title":"Eur J Immunol"},{"issue":"1","key":"ref108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","article-title":"Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains","volume":"152","author":"KC Parker","year":"1994","journal-title":"The Journal of Immunology"},{"issue":"6","key":"ref109","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1128\/JVI.02256-06","article-title":"Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients","volume":"81","author":"DW Liu","year":"2007","journal-title":"J Virol"},{"issue":"3","key":"ref110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/JVI.01768-06","article-title":"HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein","volume":"81","author":"M Nakagawa","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"ref111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.yexmp.2011.10.002","article-title":"Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses","volume":"92","author":"M Mizuuchi","year":"2012","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"ref112","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ijc.22312","article-title":"Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope","volume":"120","author":"S Morishima","year":"2007","journal-title":"International journal of cancer"},{"issue":"5","key":"ref113","first-page":"1371","article-title":"Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer","volume":"27","author":"M Hara","year":"2005","journal-title":"Int J Oncol"},{"issue":"5","key":"ref114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/CJI.0b013e31803240fa","article-title":"Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer","volume":"30","author":"I Zehbe","year":"2007","journal-title":"J Immunother"},{"issue":"38","key":"ref115","doi-asserted-by":"crossref","first-page":"29608","DOI":"10.1074\/jbc.M110.126722","article-title":"A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers","volume":"285","author":"AB Riemer","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"ref116","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellimm.2011.04.005","article-title":"Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11","volume":"270","author":"M Matijevic","year":"2011","journal-title":"Cell Immunol"},{"issue":"8","key":"ref117","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/1521-4141(2000)30:8<2281::AID-IMMU2281>3.0.CO;2-N","article-title":"Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif","volume":"30","author":"I Bourgault Villada","year":"2000","journal-title":"Eur J Immunol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-4-55","article-title":"Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid","volume":"4","author":"L Mora-Garcia Mde","year":"2006","journal-title":"J Transl Med"},{"issue":"3","key":"ref119","first-page":"788s","article-title":"Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7","volume":"7","author":"MP Rudolf","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-1702(98)00008-2","article-title":"Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors","volume":"54","author":"H Yoon","year":"1998","journal-title":"Virus research"},{"issue":"20","key":"ref121","first-page":"5792","article-title":"Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice","volume":"62","author":"GL Eiben","year":"2002","journal-title":"Cancer Res"},{"issue":"5","key":"ref122","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1128\/CDLI.11.5.889-896.2004","article-title":"Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins","volume":"11","author":"M Nakagawa","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"5","key":"ref123","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.20794","article-title":"Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer","volume":"114","author":"S Oerke","year":"2005","journal-title":"International journal of cancer"},{"issue":"11","key":"ref124","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.154.11.5934","article-title":"Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A* 0201-binding peptides","volume":"154","author":"ME Ressing","year":"1995","journal-title":"The Journal of Immunology"},{"key":"ref125","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients","volume":"129","author":"A Ferrara","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"ref126","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.154.11.5934","article-title":"Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides","volume":"154","author":"ME Ressing","year":"1995","journal-title":"J Immunol"},{"issue":"3","key":"ref127","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.10940","article-title":"Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination","volume":"104","author":"A Kather","year":"2003","journal-title":"International journal of cancer"},{"issue":"8","key":"ref128","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.4049\/jimmunol.152.8.3904","article-title":"Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins","volume":"152","author":"WM Kast","year":"1994","journal-title":"The Journal of Immunology"},{"key":"ref129","article-title":"Semin Immunol","author":"R Arens","year":"2013"},{"key":"ref130","first-page":"77","article-title":"Adv Immunol","volume":"114","author":"ED Quakkelaar","year":"2012"},{"key":"ref131","first-page":"51","article-title":"Adv Immunol","volume":"114","author":"T van Hall","year":"2012"},{"issue":"2","key":"ref132","first-page":"252","article-title":"Therapeutic vaccination against human papilloma virus induced malignancies","volume":"23","author":"SH Van Der Burg","year":"2011"},{"issue":"1","key":"ref133","first-page":"29","article-title":"Immunologic treatments for precancerous lesions and uterine cervical cancer","volume":"33","author":"P Vici","year":"2014"},{"issue":"9","key":"ref134","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"CJM Melief","year":"2015","journal-title":"The Journal of Clinical Investigation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:03:19Z","timestamp":1693994599000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205933"}},"subtitle":[],"editor":[{"given":"Craig","family":"Meyers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":134,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205933","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]}}}